Trials / Completed
CompletedNCT00656734
Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.
A Phase 1, Open-Label, Multicenter Dose-escalation, Multidose Study of MDX1411 Administered Every 14 Days in Subjects With Advanced or Recurrent Clear Cell Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the highest and safest tolerated dose of MDX-1411 for the treatment of clear cell renal cell carcinoma (Kidney cancer).
Detailed description
Subjects will be assigned one dose upon enrollment and will continue with the same dose throughout the study. The maximum duration for the study is two and a half years for a total of 17 cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MDX 1411 | MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2008-04-11
- Last updated
- 2013-05-14
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00656734. Inclusion in this directory is not an endorsement.